Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Caprelsa
Vandetanib is a small molecule kinase inhibitor indicated for the treatment of medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. It inhibits multiple receptor tyrosine kinases (RTKs), including RET, VEGFR, and EGFR, which are involved in tumor growth and angiogenesis. Vandetanib is an oral medication typically administered once daily.
For the treatment of medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
QT interval prolongation, Torsades de Pointes, sudden death, interstitial lung disease, and cardiac failure.
Outcome:
Increased vandetanib concentrations
Mechanism:
Inhibition of CYP3A4 metabolism
Outcome:
Reduced vandetanib absorption
Mechanism:
Chelation/altered pH
Outcome:
No clinically significant interaction expected
Mechanism:
N/A
Most likely new formulation: Extended-release formulation to improve patient compliance (Year 2025, 80% confidence)
Based on current usage trends and emerging clinical trial data, there is a 70% likelihood of vandetanib expanding its indications to include other RET-driven cancers within the next 5 years.
Kinase Inhibitor, Antineoplastic
Quinoline derivative